Ischemic optic neuropathy and giant cell arteritis.

Area of Science:

• Ophthalmology
• Neurology
• Vascular Medicine

Background:

• Anterior ischemic optic neuropathy (AION) is a leading cause of acute vision loss.
• Arteritic AION (AAION) and nonarteritic AION (NAION) have distinct etiologies and management challenges.
• Current understanding of NAION pathophysiology and treatment is limited, posing a therapeutic problem.

Purpose of the Study:

• To review the current understanding of AION, focusing on therapeutic challenges in NAION.
• To explore potential diagnostic and therapeutic advancements for NAION.
• To discuss alternative immunosuppressive agents for AAION due to steroid resistance.

Main Methods:

• Literature review of pathophysiology and investigation of AAION and NAION.
• Discussion of emerging diagnostic markers for prothrombotic states in NAION.
• Exploration of novel therapeutic strategies, including calcium channel blockers.

Main Results:

• AAION management requires prompt diagnosis and treatment, often with steroids, but alternatives are needed due to side effects and resistance.
• NAION presents therapeutic challenges due to difficulties in measuring optic nerve head blood flow.
• Prothrombotic states (e.g., activated protein C resistance) may be implicated in NAION etiology.
• Calcium channel blockers show promise for mitigating cellular ischemic effects in NAION.

Conclusions:

• Acute AION necessitates urgent evaluation and treatment.
• Further research into NAION pathophysiology and blood flow measurement is crucial for effective treatment.
• Investigating prothrombotic factors and exploring novel therapies like calcium channel blockers may improve outcomes for NAION patients.